Linkedin reporter Zoe Peterkin wrote up some questions she submitted to me and the file linked below is the full article. I think it will be useful as a concise outlining of Quietmind Foundation's experience providing neuroteedback combined with photobiomodulation (light therapy) to stop and reverse dementia symptoms. Our recruiting has started to work such that we now need only 20 more subjects for our study. Pleaase call 610-940-0488 for details.
Photobiomodulation: How light protects our memory
Photobiomodulation is a process that uses infrared light to stimulate our body. At an early age we learn that the sun is responsible for all life on earth. It should come as no surprise then, that research now suggests that a specific kind of light from the sun can help heal illnesses, stopping, or even reversing dementia or memory loss. Today, the search for a memory loss cure is often focused on a new drug. Photobiomodulation offers an approach that isn’t invasive and doesn’t rely on another medication.
What is Photobiomodulation or PBM?
We’ve all seen the spectrum of light from blue to red that’s created when white light shines through a prism. The band of light that’s just beyond the red that our eyes can see is called infrared and has very special properties that are key to sustaining life.
One of Infrared’s ‘special properties’ is that it can stimulate blood flow and the body’s own repair functions by increasing the available energy in our cells to make repairs and clear away damage. Understanding how Infrared can improve health and wellness has been the central focus of our research and treatment programs at Quietmind Foundation.
How Photobiomodulation helps memory loss
Since 2007, we have worked to understand how PBM and light therapy can improve memory loss in people with memory loss or dementia. To harness the power of infrared we use two light therapy devices: Cognitolite and Vielight.
Cognitolite was developed in the UK and studied by researchers at Durham University’s Department of Neuronal Physics. Quietmind has been studying this device for 13 years. The Cognitolite uses 1068nm pulsed infrared LEDs that covers the whole head and shines light into the eyes. Cognitolite uses 1100
Another device we use is the Vielight. It is much smaller and made in Malaysia and marketed from Canada. It was cleared by the FDA for general wellness. Quietmind has studied this device since 2015.
It has 5 powerful diodes compared to the Cognitolite’s 1100 LEDs and also has a diode that is inserted into one nostril to stimulate the nasal blood vessels. Our 13 years of clinical research experience has convinced us that combining neurofeedback and infrared light therapy using the Cognitolite or the Vielight, are worthwhile investments in healing and protecting our brain’s healthy functioning.
Have you or someone you know experienced memory loss?
Quietmind Foundation is recruiting subjects who are interested in joining a clinical trials using the Cognitolite device at home for 2 months.
The theory about how reducing beta amyloid plaque could positively effect dementia symptoms has now been shown to be true in a recent report on the drug aducanumab which is an antibody therapy. The medication is likely to be brought to market once approval is obtained and Biogen is going to apply for approval in early 2020.
This drug study result supports what we already know about transcranial photobiomodulation (TPBM) with 1068nm pulsed infrared light stimulation. We also know that there are no adverse side effects with TPBM and the cost of treatment is almost certainly going to be significantly less than lifelong treatment with aducanumab.
Quietmind Foundation has been providing integrative therapy that combines TPBM with home- based, brainwave biofeedback also called neurofeedback) training (NFB) that eliminates the underlying beta amyloid plaque while also increasing mitochondrial health and productivity with NFB to help repair our disrupted brain electrical networks independent of drug or other invasive procedures and unwanted side effects. QMF's longer-term therapy programs are conducted entirely at home by the patient and caregivers, with online training, clinical guidance, and periodic neuropsychiatric and neuropsychophsyiological evaluations at Quietmind Foundation's offices in Philadelphia, New York City, and Los Angeles. Please call Marvin Berman PhD at 610-940-0488 to be considered for one of our ongoing clinical trials or our longer-term comprehensive and individualized neurodegeneration treatment program.
This article points at the fact that dysregulation of brain activity directly influences quality and lifespan itself. Overactivity is another way of describing dysregulated activity or in the parlance of neurotherapeutics, its inefficient brain activity. What we want as we age is to be more efficient in our movement and our thinking, this is what often is referred to as the 'wisdom of age'. The work we do at QMF developing applications of digital neurotherapeutics(TM) is at its core, focused on enhancing neural efficiency and making sure we don't waste any of those little grey cells that Hercule Poirot depends on to solve the case. Our efforts are fixed on creating ways of noninvasively improving and maintaining optimal brain performance by maximizing neural efficiency.
This paper suggests a novel and important aspect of the neurodegenerative process that needs to be better understood. We do know from studies at Durham University in the UK that 1065-1075nm light stimulation will enhance health and protect neurons from damage and thereby reduce the amount of fragments being created that may increase neural inflammation. Further research is needed to determine if the immune system is also enhanced in being able to remove these fragments more efficiently. Read about the study here:
Clinical trials at Quietmind Foundation using the 1065-1075nm pulsed infrared helmet are ongoing and people with diagnoses of early to mid-stage dementia are encouraged to contact Dr. Berman 610-940-0488 to discuss eligibility for the new home-based 60-day light therapy program.
We see the new technologies are all set to revolutionize medical care and personal growth. I"m very excited to see the range of noninvasive technologies being described especially transcranial ultrasound. Quietmind is going to explore this option in future research projects at its clinic in Elkins Park.
We need to be more conscious of the risks of even a single head trauma given the findings here about the connection to developing memory disorders including Alzheimer's disease. This is why children playing sports should be evaluated regularly for signs of dysregulated brain activity and steps taken to correct these patterns including home-based neurofeedback training and photobiomodulation.
Protein tangles linked with dementia seen in patients after single head injuryhttps://www.sciencedaily.com/releases/2019/09/190905103013.htm
Abstract: The primary goal of the present research is to study the effect of a neurofeedback training (NFT) period on balance problems associated with Parkinson’s disease. Sixteen patients were selected through purposive sampling and were randomly divided into experimental and control groups. The research procedure included eight sessions. Prior to and after training, pre-tests and post-tests of static and dynamic balance were administered using ‘‘limit of stability’’ for the Biodex as well as the Berg scale. The results revealed that, after neurofeedback training, a statistically significant improvement in both static and dynamic balance in the experimental group was achieved. The means of the Biodex and Berg scores in the experimental group increased from 18.87 to 42.87 and 17.62 to 46.37, respectively. The means of the Biodex and Berg scores in the control group in the pretest were 18.25 and 17.75 and increased to 20.00 and 20.50, respectively. The results suggest that NFT can improve static and dynamic balance in PD patients.
The application of infrared light stimulation to treat the underlying disease processes in dementia are readily explained in this excellent review paper by Michael Hamblin. I think there is now ample support for seeing this as an effective noninvasive, non-drug treatment especially when combined with brainwave biofeedback and functional medicine as described by Dale Bredesen and those following his model of treatment. Quietmind Fdn. has long promoted this tripartite treatment approach in our clinic and in our consultation with other providers and clinics around the world.
New blood markers that reflect risk for Alzheimer’s disease (AD) are uncovering important modifiable risk factors to be aware of to dramatically reduce the likelihood of ever suffering from this cruel disease. The latest study shows that just one night of sleep disruption is associated with an increase in these blood markers.
The primary brain lesions of AD are the result of deposits of a substance known as beta-amyloid. Although the immune cells in the brain normally remove beta-amyloid and plaque, research is beginning to characterize a chronic and excessive inflammatory reaction to amyloid proteins in the brain in susceptible individuals that can promote AD. Blood measurements of a protein called tau that is formed from toxic beta-amyloid as well as a protein that acts as the internal skeleton of brain cells known neurofilament light chain (NfL) protein can predict neurodegeneration years before clinical symptoms appear in AD. When brain cells are damaged, tau and NfL are released into cerebrospinal fluid and then the blood.
Poor sleep quality is associated with a significant risk for Alzheimer’s disease. For example, researchers from the Washington University School of Medicine in St. Louis found that the inability to sleep through the night was associated with an increased risk the preclinical form of Alzheimer’s disease. Subjects who were the least efficient sleepers in the study were five times more likely to have preclinical form of Alzheimer's. While researchers are exploring the formation of the beta-amyloid as being the cause of the poor sleep quality, a more likely explanation is that the poor sleep quality is actually the cause of the beta-amyloid formation.
During the deeper levels of sleep the repair mechanisms and antioxidant system of brain cells are heightened. Sleeping pills seem to exacerbate this situation. Use of sedative hypnotic drugs (sleeping pills) was associated with a whopping 230% increase risk of AD over an eight-year period in a study in France while in a study in the U.K., the risk was even greater over a 22-year follow up study– a dramatic 294% increase. The link between sleeping pill usage and the dramatic increased risk for AD may be the result of the fact that these drugs typically negatively impact the ability to achieve deeper levels of sleep.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.